Abstract
Pathological Gambling (PG) is characterized by “the failure to resist gambling impulses despite severe personal, family or occupational consequences”. PG estimated prevalence ranges between 0.4% and 3.4% within the adult population. PG seems to be more common in patients with Parkinson’s disease (PD) than in the general population. In the past few years, PG has been reported as a side effect of dopamine agonist (DA) therapy used in PD. This association has aroused great interest for the dramatic impact PG has on patients’ quality of life. Management of PG in patients with PD could be demanding. It is based on patient and caregiver education, modification of dopamine replacement therapy, and in some cases psychoactive drug administration. This review describes possible pathogenesis of PG associated with DA therapy, available pharmacological treatments and management approaches that may increase the likelihood of satisfactory treatment outcomes in PD patients.
Keywords: Behavioural therapy, dopamine agonists, impulse control disorders, Parkinson’s disease, pathological gambling, pharmacological therapy, DA therapy, dopamine dysregulation syndrome, OC spectrum disorders, compulsive eating, Mood disorders , impulsivity, Non-ergot dopamine agonists, pharmacologic treatment, Parkinsonism
Current Psychopharmacology
Title:Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Volume: 1
Author(s): Domenico Pirritano, Massimiliano Plastino, Antonietta Fava, Dario Cristiano, Luca Gallelli, Carmela Colica and Domenico Bosco
Affiliation:
Keywords: Behavioural therapy, dopamine agonists, impulse control disorders, Parkinson’s disease, pathological gambling, pharmacological therapy, DA therapy, dopamine dysregulation syndrome, OC spectrum disorders, compulsive eating, Mood disorders , impulsivity, Non-ergot dopamine agonists, pharmacologic treatment, Parkinsonism
Abstract: Pathological Gambling (PG) is characterized by “the failure to resist gambling impulses despite severe personal, family or occupational consequences”. PG estimated prevalence ranges between 0.4% and 3.4% within the adult population. PG seems to be more common in patients with Parkinson’s disease (PD) than in the general population. In the past few years, PG has been reported as a side effect of dopamine agonist (DA) therapy used in PD. This association has aroused great interest for the dramatic impact PG has on patients’ quality of life. Management of PG in patients with PD could be demanding. It is based on patient and caregiver education, modification of dopamine replacement therapy, and in some cases psychoactive drug administration. This review describes possible pathogenesis of PG associated with DA therapy, available pharmacological treatments and management approaches that may increase the likelihood of satisfactory treatment outcomes in PD patients.
Export Options
About this article
Cite this article as:
Pirritano Domenico, Plastino Massimiliano, Fava Antonietta, Cristiano Dario, Gallelli Luca, Colica Carmela and Bosco Domenico, Pathological Gambling in Parkinson’s Disease: An Update on Medical Management, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040365
DOI https://dx.doi.org/10.2174/2211556011201040365 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook
Current Medicinal Chemistry Impact of Metformin on Male Reproduction
Current Pharmaceutical Design 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Evidence Based Psychosocial Practices and Recovery from Schizophrenia
Current Psychiatry Reviews Episcleritis and Scleritis in Rheumatic Disease
Current Rheumatology Reviews Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets Relevant Modulation by Ferrous Ions of N-Methyl-D-Aspartate Receptors in Ischemic Brain Injuries
Current Neurovascular Research Lipid Membrane; A Novel Target for Viral and Bacterial Pathogens
Current Drug Targets Role of Brain NUCB2/nesfatin-1 in the Stress-induced Modulation of Gastrointestinal Functions
Current Neuropharmacology Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Therapeutic Effects of Quetiapine on Memory Deficit and Brain β-Amyloid Plaque Pathology in a Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Signal-Dependent Noise Induces Muscle Co-Contraction to Achieve Required Movement Accuracy: A Simulation Study with an Optimal Control
Current Bioinformatics Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis
Adolescent Psychiatry A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal Fetal Determinants of Type 2 Diabetes
Current Drug Targets